PARP-1 inhibition in IL-1β-stimulated rat chondrocytes and ACLT rat osteoarthritis
In rat cell and ACLT-model experiments, inhibiting PARP-1 reduced inflammatory and cartilage-degrading markers, alleviated chondrocyte senescence and lessened cartilage degradation; the abstract calls PARP-1 a potential therapeutic target, not a proven treatment. [1]
Automatic summary · not editorially reviewed
The key findings
In vitro, rat chondrocytes stimulated with IL-1β showed elevated PARP-1 expression and activity. [1]
PARP-1 inhibition reduced iNOS, COX2, MMP13 and ADAMTS5 and alleviated senescence markers, partly reversed by EX527. [1]
Intra-articular PARP-1 siRNA in ACLT rats alleviated cartilage degradation by staining and Mankin scoring. [1]
The source at a glance
- Study type / format
- Preclinical in vitro and in vivo rat study (abstract)
- Population / context
- Rat chondrocytes stimulated with IL-1β and rats with ACLT-induced osteoarthritis
- Summary based on
- Study abstract
- Original publication
- August 22, 2026
IL-1β-stimulated rat chondrocytes and PARP-1 activity
The abstract describes osteoarthritis as a degenerative joint disease with cartilage destruction, inflammation and chondrocyte senescence, and states that no disease-modifying therapies are currently available. In vitro, rat chondrocytes were stimulated with interleukin-1β (IL-1β) to create an osteoarthritis-like phenotype. PARP-1 expression and activity were elevated after this stimulation. The researchers then inhibited PARP-1 with specific small interfering RNA (siRNA).
Supporting source [1]
Reduced inflammatory markers and senescence in stimulated chondrocytes
PARP-1 inhibition by siRNA significantly reduced pro-inflammatory mediators (iNOS, COX2) and matrix-degrading enzymes (MMP13, ADAMTS5). It also alleviated IL-1β-induced NAD depletion and chondrocyte senescence, shown by decreased p16 expression and fewer SA-β-gal-positive cells. A SIRT1 inhibitor, EX527, partially reversed these effects. Mechanistically, PARP-1 inhibition suppressed IL-1β-induced NF-κB activation by reducing IκB and p65 phosphorylation and inhibiting p65 nuclear translocation; co-immunoprecipitation revealed an interaction between PARP-1 and IκB.
Supporting source [1]
Intra-articular siRNA in ACLT rat model and abstract scope
In vivo, intra-articular injection of PARP-1 siRNA in an anterior cruciate ligament transection (ACLT)-induced rat osteoarthritis model alleviated cartilage degradation, as shown by Safranin O/toluidine blue staining and Mankin scoring. The abstract concludes that PARP-1 inhibition attenuates osteoarthritis progression by suppressing NF-κB signaling and alleviating chondrocyte senescence, and suggests PARP-1 as a potential therapeutic target. These are preclinical rat findings; the abstract reports no human data, no clinical outcomes and no dosing information.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Findings come from rat chondrocyte and ACLT rat experiments, not human studies, and the abstract reports no clinical outcomes or dosing.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Zhang R, Wang L, Pei W, Qu Y, You H. · europepmc.org · August 22, 2026